Skip to main content
×
×
Home

Predicting relapse after antidepressant withdrawal – a systematic review

  • I. M. Berwian (a1) (a2), H. Walter (a3), E. Seifritz (a1) and Q. J. M. Huys (a1) (a2)
Abstract

A substantial proportion of the burden of depression arises from its recurrent nature. The risk of relapse after antidepressant medication (ADM) discontinuation is high but not uniform. Predictors of individual relapse risk after antidepressant discontinuation could help to guide treatment and mitigate the long-term course of depression. We conducted a systematic literature search in PubMed to identify relapse predictors using the search terms ‘(depress* OR MDD*) AND (relapse* OR recurren*) AND (predict* OR risk) AND (discontinu* OR withdraw* OR maintenance OR maintain or continu*) AND (antidepress* OR medication OR drug)’ for published studies until November 2014. Studies investigating predictors of relapse in patients aged between 18 and 65 years with a main diagnosis of major depressive disorder (MDD), who remitted from a depressive episode while treated with ADM and were followed up for at least 6 months to assess relapse after part of the sample discontinued their ADM, were included in the review. Although relevant information is present in many studies, only 13 studies based on nine separate samples investigated predictors for relapse after ADM discontinuation. There are multiple promising predictors, including markers of true treatment response and the number of prior episodes. However, the existing evidence is weak and there are no established, validated markers of individual relapse risk after antidepressant cessation. There is little evidence to guide discontinuation decisions in an individualized manner beyond overall recurrence risk. Thus, there is a pressing need to investigate neurobiological markers of individual relapse risk, focusing on treatment discontinuation.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Predicting relapse after antidepressant withdrawal – a systematic review
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Predicting relapse after antidepressant withdrawal – a systematic review
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Predicting relapse after antidepressant withdrawal – a systematic review
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
*Address for correspondence: I. M. Berwian, Translational Neuromodeling Unit, Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Wilfriedstrasse 6, 8032 Zürich, Switzerland. (Email: isabel.berwian@oxon.org)
References
Hide All
American Psychiatric Association (2000). Diagnostic and Statistical Manual Text Revision (DSM-IV-TR) . American Psychiatric Association: Washington, DC.
Andrews, PW, Kornstein, SG, Halberstadt, LJ, Gardner, CO, Neale, MC (2011). Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Frontiers in Psychology 2, 159.
Baldessarini, RJ, Lau, WK, Sim, J, Sum, MY, Sim, K (2015). Duration of initial antidepressant treatment and subsequent relapse of major depression. Journal of Clinical Psychopharmacology 35, 7576.
Bauer, M, Pfennig, A, Severus, E, Whybrow, PC, Angst, J, Möller, H-J (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World Journal of Biological Psychiatry 14, 334385.
Berlanga, C, Heinze, G, Torres, M, Apiquián, R, Caballero, A (1999). Personality and clinical predictors of recurrence of depression. Psychiatric Services 50, 376380.
Burcusa, SL, Iacono, WG (2007). Risk for recurrence in depression. Clinical Psychology Review 27, 959985.
Chekroud, AM, Zotti, RJ, Shehzad, Z, Gueorguieva, R, Johnson, MK, Trivedi, MH, Cannon, TD, Krystal, JH, Corlett, PR (2016). Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 3, 243250.
Dunlop, BW, Holland, P, Bao, W, Ninan, PT, Keller, MB (2012). Recovery and subsequent recurrence in patients with recurrent major depressive disorder. Journal of Psychiatric Research 46, 708715.
El-Mallakh, PRS, Briscoe, B (2012). Studies of long-term use of antidepressants. CNS Drugs 26, 97109.
Farb, NAS, Anderson, AK, Bloch, RT, Segal, ZV (2011). Mood-linked responses in medial prefrontal cortex predict relapse in patients with recurrent unipolar depression. Biological Psychiatry 70, 366372.
Fava, M, Wiltse, C, Walker, D, Brecht, S, Chen, A, Perahia, D (2009). Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. Journal of Affective Disorders 113, 263271.
Frank, E, Prien, RF, Jarrett, RB, Keller, MB, Kupfer, DJ, Lavori, PW, Rush, AJ, Weissman, MM (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Archives of General Psychiatry 48, 851855.
Geddes, JR, Carney, SM, Davies, C, Furukawa, TA, Kupfer, DJ, Frank, E, Goodwin, GM (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653661.
Glue, P, Donovan, MR, Kolluri, S, Emir, B (2010). Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Australian and New Zealand Journal of Psychiatry 44, 697705.
Hardeveld, F, Spijker, J, De Graaf, R, Nolen, WA, Beekman, ATF (2010). Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatrica Scandinavica 122, 184191.
Hochstrasser, B, Isaksen, PM, Koponen, H, Lauritzen, L, Mahnert, FA, Rouillon, F, Wade, AG, Andersen, M, Pedersen, SF, Swart, JCGD, Nil, R (2001). Prophylactic effect of citalopram in unipolar, recurrent depression. British Journal of Psychiatry 178, 304310.
Hollon, SD, DeRubeis, RJ, Shelton, RC, Amsterdam, JD, Salomon, RM, O'Reardon, JP, Lovett, ML, Young, PR, Haman, KL, Freeman, BB, Gallop, R (2005). Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry 62, 417422.
Hunot, VM, Horne, R, Leese, MN, Churchill, RC (2007). A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Primary Care Companion to the Journal of Clinical Psychiatry 9, 9199.
Huys, QJM, Moutoussis, M, Williams, J (2011). Are computational models of any use to psychiatry? Neural Networks 24, 544551.
Iovieno, N, van Nieuwenhuizen, A, Clain, A, Baer, L, Nierenberg, AA (2011). Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depression and Anxiety 28, 137144.
Joliat, MJ, Schmidt, ME, Fava, M, Zhang, S, Michelson, D, Trapp, NJ, Miner, CM (2004). Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. Journal of Clinical Psychiatry 65, 373378.
Kaymaz, N, van Os, J, Loonen, AJM, Nolen, WA (2008). Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. Journal of Clinical Psychiatry 69, 14231436.
Keller, MB, Kocsis, JH, Thase, ME, Gelenberg, AJ, Rush, AJ, Koran, L, Schatzberg, A, Russell, J, Hirschfeld, R, Klein, D, Mccullough, JP, Fawcett, JA, Kornstein, S, Lavange, L, Harrison, W (1998). Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. Journal of the American Medical Association 280, 16651672.
Keller, MB, Trivedi, MH, Thase, ME, Shelton, RC, Kornstein, SG, Nemeroff, CB, Friedman, ES, Gelenberg, AJ, Kocsis, JH, Dunner, DL, Hirschfeld, RMA, Rothschild, AJ, Ferguson, JM, Schatzberg, AF, Zajecka, JM, Pedersen, RD, Yan, B, Ahmed, S, Musgnung, J, Ninan, PT (2007). The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. Journal of Clinical Psychiatry 68, 12461256.
Kendler, KS, Thornton, LM, Gardner, CO (2000). Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the “Kindling” hypothesis. American Journal of Psychiatry 157, 12431251.
Kessler, RC, Berglund, P, Demler, O, Jin, R, Koretz, D, Merikangas, KR, Rush, AJ, Walters, EE, Wang, PS; National comorbidity survey Replication (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 30953105.
Khan, A, Bhat, A, Kolts, R, Thase, ME, Brown, W (2010). Why has the antidepressant–placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neuroscience and Therapeutics 16, 217226.
Kornstein, SG, Pedersen, RD, Holland, PJ, Nemeroff, CB, Rothschild, AJ, Thase, ME, Trivedi, MH, Ninan, PT, Keller, MB (2014). Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study. Journal of Clinical Psychiatry 75, 6268.
Lythe, KE, Moll, J, Gethin, JA, Workman, CI, Green, S, Lambon Ralph, MA, Deakin, JF, Zahn, R, (2015). Self-blame–selective hyperconnectivity between anterior temporal and subgenual cortices and prediction of recurrent depressive episodes. JAMA Psychiatry 72, 11191126.
McGrath, PJ, Stewart, JW, Petkova, E, Quitkin, FM, Amsterdam, JD, Fawcett, J, Reimherr, FW, Rosenbaum, JF, Beasley, CM (2000). Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. Journal of Clinical Psychiatry 61, 518524.
McGrath, PJ, Stewart, JW, Quitkin, FM, Chen, Y, Alpert, JE, Nierenberg, AA, Fava, M, Cheng, J, Petkova, E (2006). Predictors of relapse in a prospective study of fluoxetine treatment of major depression. American Journal of Psychiatry 163, 15421548.
Monroe, SM, Harkness, KL (2005). Life stress, the ‘Kindling’ hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychological Review 112, 417445.
Monroe, SM, Harkness, KL (2011). Recurrence in major depression: a conceptual analysis. Psychological Review 118, 655674.
Montague, PR, Dolan, RJ, Friston, KJ, Dayan, P (2012). Computational psychiatry. Trends in Cognitive Sciences 16, 7280.
National Collaborating Centre for Mental Health (UK) (2010). Depression: The Treatment and Management of Depression in Adults (Updated Edition) . National Institute for Health and Clinical Excellence: Guidance. British Psychological Society: Leicester, UK.
Nierenberg, AA, Husain, MM, Trivedi, MH, Fava, M, Warden, D, Wisniewski, SR, Miyahara, S, Rush, AJ (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychological Medicine 40, 4150.
Nierenberg, AA, Quitkin, FM, Kremer, C, Keller, MB, Thase, ME (2004). Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 29, 10121018.
Olfson, M, Marcus, SC, Tedeschi, M, Wan, GJ (2006). Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry 163, 101108.
Palmer, DM (2015). Biomarkers for antidepressant selection: iSPOT-D Study. Current Behavioral Neuroscience Reports 2, 137145.
Perahia, DG, Gilaberte, I, Wang, F, Wiltse, CG, Huckins, SA, Clemens, JW, Montgomery, SA, Montejo, AL, Detke, MJ (2006). Duloxetine in the prevention of relapse of major depressive disorder. British Journal of Psychiatry 188, 346353.
Quitkin, FM, Rabkin, JD, Markowitz, JM, Stewart, JW, McGrath, PJ, Harrison, W (1987). Use of pattern analysis to identify true drug response: a replication. Archives of General Psychiatry 44, 259264.
Rothschild, AJ, Dunlop, BW, Dunner, DL, Friedman, ES, Gelenberg, A, Holland, P, Kocsis, JH, Kornstein, SG, Shelton, R, Trivedi, MH, Zajecka, JM, Goldstein, C, Thase, ME, Pedersen, R, Keller, MB (2009). Assessing rates and predictors of tachyphylaxis during the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) Study. Psychopharmacology Bulletin 42, 520.
Rouillon, F, Berdeaux, G, Bisserbe, JC, Warner, B, Mesbah, M, Smadja, C, Chwalow, J (2000). Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. Journal of Affective Disorders 58, 171180.
Rush, AJ, Trivedi, MH, Wisniewski, SR, Nierenberg, AA, Stewart, JW, Warden, D, Niederehe, G, Thase, ME, Lavori, PW, Lebowitz, BD, McGrath, PJ, Rosenbaum, JF, Sackeim, HA, Kupfer, DJ, Luther, J, Fava, M (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163, 19051917.
Schmidt, ME, Fava, M, Robinson, JM, Judge, R (2000). The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. Journal of Clinical Psychiatry 61, 851857.
Sim, K, Lau, WK, Sim, J, Sum, MY, Baldessarini, RJ (2015). Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. International Journal of Neuropsychopharmacology 19, pyv076.
Stewart, JW, Quitkin, FM, McGrath, PJ, Amsterdam, J, Fava, M, Fawcett, J, Reimherr, F, Rosenbaum, J, Beasley, C, Roback, P (1998). Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Archives of General Psychiatry 55, 334343.
Szegedi, A, Jansen, WT, Van Willigenburg, APP, Van Der Meulen, E, Stassen, HH, Thase, ME (2009). Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. Journal of Clinical Psychiatry 70, 344353.
Thase, ME, Nierenberg, AA, Keller, MB, Panagides, J; Relapse Prevention Study Group (2001). Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. Journal of Clinical Psychiatry 62, 782788.
Trinh, N-HT, Shyu, I, McGrath, PJ, Clain, A, Baer, L, Fava, M, Yeung, A (2011). Examining the role of race and ethnicity in relapse rates of major depressive disorder. Comprehensive Psychiatry 52, 151155.
Viguera, AC, Baldessarini, RJ, Friedberg, J (1998). Discontinuing antidepressant treatment in major depression. Harvard Review of Psychiatry 5, 293306.
Whiteford, HA, Degenhardt, L, Rehm, J, Baxter, AJ, Ferrari, AJ, Erskine, HE, Charlson, FJ, Norman, RE, Flaxman, AD, Johns, N, Burstein, R, Murray, CJ, Vos, T (2013). Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382, 15751586.
Wolfers, T, Buitelaar, JK, Beckmann, CF, Franke, B, Marquand, AF (2015). From estimating activation locality to predicting disorder: a review of pattern recognition for neuroimaging-based psychiatric diagnostics. Neuroscience and Biobehavioral Reviews 57, 328349.
Yang, H, Chuzi, S, Sinicropi-Yao, L, Johnson, D, Chen, Y, Clain, A, Baer, L, McGrath, PJ, Stewart, JW, Fava, M, Papakostas, GI (2009). Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. European Archives of Psychiatry and Clinical Neuroscience 260, 145150.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 43
Total number of PDF views: 591 *
Loading metrics...

Abstract views

Total abstract views: 906 *
Loading metrics...

* Views captured on Cambridge Core between 27th October 2016 - 26th April 2018. This data will be updated every 24 hours.